GlassScriptPhysician profile
Ryan Michael Kelley
NPI 1346855517
$4,645.20
in general payments reported to CMS, 2019-2025
20 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $966 · 2023: $1,248 · 2024: $537 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $585.60 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $570.41 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $525.55 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Neurocrine Biosciences, INC. | $454.03 | 2021-2025 | Ingrezza |
| Abbvie INC. | $452.67 | 2021-2025 | |
| Lundbeck LLC | $425.92 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $410.92 | 2021-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $327.99 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $309.98 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Corium, LLC | $110.56 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $98.35 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $85.70 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $75.80 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $52.67 | 2022-2024 | Auvelity |
| Neos Therapeutics, LP | $35.40 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33.44 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $32.89 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.04 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.39 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.